1. Home
  2. FULC vs CINGW Comparison

FULC vs CINGW Comparison

Compare FULC & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FULC
  • CINGW
  • Stock Information
  • Founded
  • FULC 2015
  • CINGW N/A
  • Country
  • FULC United States
  • CINGW United States
  • Employees
  • FULC N/A
  • CINGW 13
  • Industry
  • FULC Biotechnology: Pharmaceutical Preparations
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • FULC Health Care
  • CINGW Health Care
  • Exchange
  • FULC Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • FULC N/A
  • CINGW N/A
  • IPO Year
  • FULC 2019
  • CINGW 2021
  • Fundamental
  • Price
  • FULC $6.88
  • CINGW $0.04
  • Analyst Decision
  • FULC Hold
  • CINGW
  • Analyst Count
  • FULC 7
  • CINGW 0
  • Target Price
  • FULC $6.29
  • CINGW N/A
  • AVG Volume (30 Days)
  • FULC 903.4K
  • CINGW N/A
  • Earning Date
  • FULC 05-01-2025
  • CINGW N/A
  • Dividend Yield
  • FULC N/A
  • CINGW N/A
  • EPS Growth
  • FULC N/A
  • CINGW N/A
  • EPS
  • FULC N/A
  • CINGW N/A
  • Revenue
  • FULC $80,000,000.00
  • CINGW N/A
  • Revenue This Year
  • FULC N/A
  • CINGW N/A
  • Revenue Next Year
  • FULC N/A
  • CINGW N/A
  • P/E Ratio
  • FULC N/A
  • CINGW N/A
  • Revenue Growth
  • FULC 3087.25
  • CINGW N/A
  • 52 Week Low
  • FULC $2.32
  • CINGW N/A
  • 52 Week High
  • FULC $10.13
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • FULC 68.05
  • CINGW N/A
  • Support Level
  • FULC $6.03
  • CINGW N/A
  • Resistance Level
  • FULC $7.48
  • CINGW N/A
  • Average True Range (ATR)
  • FULC 0.59
  • CINGW 0.00
  • MACD
  • FULC -0.01
  • CINGW 0.00
  • Stochastic Oscillator
  • FULC 71.50
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: